Trial Profile
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Clostridium butyricum M588 (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 27 Jan 2024 Results assessing the functionality of microbial communities in patients with metastatic renal cell carcinoma receiving cabozantinib/nivolumab with or without CBM588 presented at the 2024 Genitourinary Cancers Symposium
- 28 Nov 2023 Planned End Date changed from 25 Oct 2023 to 25 Oct 2024.
- 28 Nov 2023 Planned primary completion date changed from 25 Oct 2023 to 25 Oct 2024.